ClinicalTrials.gg
CompletedNCT00349336Updated Sep 18, 2012Results posted

A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.

A Phase 3 interventional study of bevacizumab [Avastin] and XELOX in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-18.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing xelox in Colorectal Neoplasms — 12 open to participants now, 12 under way, none of them phase 3. xelox · Colorectal Neoplasms.

Enrollment
9th of 19
64 · median 54
Started
2006
with 2 others
Phase 3
2 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
1 of 19
Hoffmann-La Roche

Among the 19 studies testing xelox in Colorectal Neoplasms, this one is the 9th largest by enrollment, is one of 3 that started in 2006, is one of 2 in phase 3, and was the 1st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

12 of the 19 studies testing xelox in Colorectal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About xelox

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing xelox in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This 2 arm study will compare the pharmacokinetics and safety of Avastin at steady state under 2 different dosing regimens, in combination with XELOX (oxaliplatin + Xeloda) or FOLFOX-4 (oxaliplatin, leucovorin and 5-fluorouracil). Patients randomized to the XELOX arm will receive Avastin (7.5mg/kg iv) on Day 1 of each 3 week cycle; patients randomized to the FOLFOX-4 arm will receive Avastin (5mg/kg iv) on Day 1 of each 2 week cycle. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • adenocarcinoma of the colon or rectum, with or locally advanced disease;
  • >=1 target lesion.

Exclusion criteria

Exclusion Criteria:

  • patients who have previously received systemic treatment for advanced or disease;
  • patients who have received treatment for non-metastatic disease in past 3 months;
  • previous therapy with oxaliplatin or Avastin.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: XELOX

  • Experimental
    2

    Drug: bevacizumab [Avastin] · Drug: FOLFOX-4

Interventions

06

What researchers measure

Primary outcomes

  1. Weekly Steady-state Exposure of Bevacizumab

    Area under the serum concentration-time curve per week, at steady state (AUCss per week). Estimation of the parameter was performed using non-compartmental methods.

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Time Zero to Last Measurable Plasma Concentration of Bevacizumab

    Area under the serum concentration-time curve from time zero to the time of the last measurable plasma concentration (AUC 0-last). Estimation of the parameter was performed using non-compartmental methods.

    Time frame: Up to 48 weeks

  2. Steady-state Exposure of Bevacizumab From Time Zero to Tau

    Area under the serum concentration-time curve from time zero to tau, at steady state (AUCss 0-tau), where tau was the length of the cycle, i.e., tau = 3 weeks for XELOX+BV and tau = 2 weeks for FOLFOX-4+BEV. Estimation of the parameter was performed using non-compartmental methods.

    Time frame: Up to 48 weeks

  3. Maximum Serum Concentration of Bevacizumab at Steady State

    Maximum serum concentration at steady state (Css,max). Estimation of the parameter was performed using non-compartmental methods.

    Time frame: Up to 48 weeks

  4. Minimum Serum Concentration of Bevacizumab at Steady State

    Minimum serum concentration at steady state (Css, min). Estimation of the parameter was performed using non-compartmental methods.

    Time frame: Up to 48 weeks

  5. Serum Clearance of Bevacizumab

    Serum clearance (CL). Estimation of the parameter was performed using non-compartmental methods.

    Time frame: Up to 48 weeks

  6. Time of Maximum Serum Concentration of Bevacizumab

    Time of maximum serum concentration (tmax). Estimation of the parameter was performed using non-compartmental methods.

    Time frame: Up to 48 weeks

  7. Volume of Distribution of Bevacizumab at Steady State

    Volume of distribution at steady state (Vss). Estimation of the parameter was performed using non-compartmental methods.

    Time frame: Up to 48 weeks

  8. Terminal Half-life of Bevacizumab

    Terminal half-life (t1/2) (apparent elimination half-life). Estimation of the parameter was performed using non-compartmental methods.

    Time frame: Up to 48 weeks

07

Results

Posted Feb 26, 2010

Participant flow

A total of 64 patients in 7 centers were enrolled between 01 August 2006 to 28 May 2008. 37 were included in the pharmacokinetic (PK) analyses.

Participant flow — Overall Study
MilestoneXELOX+BevacizumabFOLFOX-4+Bevacizumab
Started3232
Completed1918
Not completed1314

Outcome measures

SecondaryTime Zero to Last Measurable Plasma Concentration of Bevacizumab

Area under the serum concentration-time curve from time zero to the time of the last measurable plasma concentration (AUC 0-last). Estimation of the parameter was performed using non-compartmental methods.

Time frame:
Up to 48 weeks
Reported as:
Mean · day*ug/mL
Time Zero to Last Measurable Plasma Concentration of Bevacizumab
day*ug/mLXELOX+BevacizumabFOLFOX-4+Bevacizumab
Time Zero to Last Measurable Plasma Concentration of Bevacizumab2457.19 ± 359.51709.8 ± 497.0
PrimaryWeekly Steady-state Exposure of Bevacizumab

Area under the serum concentration-time curve per week, at steady state (AUCss per week). Estimation of the parameter was performed using non-compartmental methods.

Time frame:
Up to 48 weeks
Reported as:
Mean · day*ug/mL
Weekly Steady-state Exposure of Bevacizumab
day*ug/mLXELOX+BevacizumabFOLFOX-4+Bevacizumab
Weekly Steady-state Exposure of Bevacizumab4090.3 ± 1047.64022.4 ± 1774.2
SecondarySteady-state Exposure of Bevacizumab From Time Zero to Tau

Area under the serum concentration-time curve from time zero to tau, at steady state (AUCss 0-tau), where tau was the length of the cycle, i.e., tau = 3 weeks for XELOX+BV and tau = 2 weeks for FOLFOX-4+BEV. Estimation of the parameter was performed using non-compartmental methods.

Time frame:
Up to 48 weeks
Reported as:
Mean · day*ug/mL
Steady-state Exposure of Bevacizumab From Time Zero to Tau
day*ug/mLXELOX+BevacizumabFOLFOX-4+Bevacizumab
Steady-state Exposure of Bevacizumab From Time Zero to Tau2457.0 ± 360.61758.4 ± 468.5
SecondaryMaximum Serum Concentration of Bevacizumab at Steady State

Maximum serum concentration at steady state (Css,max). Estimation of the parameter was performed using non-compartmental methods.

Time frame:
Up to 48 weeks
Reported as:
Mean · ug/mL
Maximum Serum Concentration of Bevacizumab at Steady State
ug/mLXELOX+BevacizumabFOLFOX-4+Bevacizumab
Maximum Serum Concentration of Bevacizumab at Steady State242 ± 31.6215.6 ± 53.2
SecondaryMinimum Serum Concentration of Bevacizumab at Steady State

Minimum serum concentration at steady state (Css, min). Estimation of the parameter was performed using non-compartmental methods.

Time frame:
Up to 48 weeks
Reported as:
Mean · ug/ml
Minimum Serum Concentration of Bevacizumab at Steady State
ug/mlXELOX+BevacizumabFOLFOX-4+Bevacizumab
Minimum Serum Concentration of Bevacizumab at Steady State59.6 ± 14.180.0 ± 25.5
SecondarySerum Clearance of Bevacizumab

Serum clearance (CL). Estimation of the parameter was performed using non-compartmental methods.

Time frame:
Up to 48 weeks
Reported as:
Mean · L/day
Serum Clearance of Bevacizumab
L/dayXELOX+BevacizumabFOLFOX-4+Bevacizumab
Serum Clearance of Bevacizumab0.236 ± 0.0510.226 ± 0.056
SecondaryTime of Maximum Serum Concentration of Bevacizumab

Time of maximum serum concentration (tmax). Estimation of the parameter was performed using non-compartmental methods.

Time frame:
Up to 48 weeks
Reported as:
Mean · hr
Time of Maximum Serum Concentration of Bevacizumab
hrXELOX+BevacizumabFOLFOX-4+Bevacizumab
Time of Maximum Serum Concentration of Bevacizumab6.442 ± 6.7864.958 ± 3.596
SecondaryVolume of Distribution of Bevacizumab at Steady State

Volume of distribution at steady state (Vss). Estimation of the parameter was performed using non-compartmental methods.

Time frame:
Up to 48 weeks
Reported as:
Mean · L
Volume of Distribution of Bevacizumab at Steady State
LXELOX+BevacizumabFOLFOX-4+Bevacizumab
Volume of Distribution of Bevacizumab at Steady State4.932 ± 1.4094.908 ± 1.563
SecondaryTerminal Half-life of Bevacizumab

Terminal half-life (t1/2) (apparent elimination half-life). Estimation of the parameter was performed using non-compartmental methods.

Time frame:
Up to 48 weeks
Reported as:
Mean · hr
Terminal Half-life of Bevacizumab
hrXELOX+BevacizumabFOLFOX-4+Bevacizumab
Terminal Half-life of Bevacizumab381.2 ± 91.7394.1 ± 121.8

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
XELOX+Bevacizumab—9/32 (28.1%)32/32 (100%)
FOLFOX-4+Bevacizumab—15/32 (46.9%)32/32 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventXELOX+BevacizumabFOLFOX-4+Bevacizumab
DiarrhoeaGastrointestinal disorders4/321/32
Abdominal PainGastrointestinal disorders0/322/32
FatigueGeneral disorders0/322/32
DehydrationMetabolism and nutrition disorders2/320/32
HypersensitivityImmune system disorders0/322/32
VomitingGastrointestinal disorders1/321/32
Gastrointestinal ObstructionGastrointestinal disorders0/321/32
IleusGastrointestinal disorders1/320/32
NauseaGastrointestinal disorders0/321/32
OesophagitisGastrointestinal disorders1/320/32
Most frequent other events
Showing 10 of 110
Most frequent other events
EventXELOX+BevacizumabFOLFOX-4+Bevacizumab
NauseaGastrointestinal disorders26/3216/32
FatigueGeneral disorders24/3223/32
DiarrhoeaGastrointestinal disorders20/3223/32
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders18/321/32
Peripheral Sensory NeuropathyNervous system disorders15/3216/32
AnorexiaMetabolism and nutrition disorders16/328/32
Temperature IntoleranceGeneral disorders15/3212/32
Neuropathy PeripheralNervous system disorders15/3215/32
NeutropeniaBlood and lymphatic system disorders4/3214/32
EpistaxisRespiratory, thoracic and mediastinal disorders7/3213/32

Baseline characteristics

Age Continuous
Age Continuous(years)XELOX+BevacizumabFOLFOX-4+BevacizumabTotal
Mean55.9 ± 12.5657.9 ± 10.8456.9 ± 11.74
Sex: Female, Male
Sex: Female, Male(Participants)XELOX+BevacizumabFOLFOX-4+BevacizumabTotal
Female131730
Male191534
08

Study locations

7 sites
  • Box Hill, 3128, Australia
  • Fitzroy, 3065, Australia
  • Sydney, 2031, Australia
  • Brampton, Ontario L6R 3J7, Canada
  • Hamilton, Ontario L8V 5C2, Canada
  • Toronto, Ontario M5G 2M9, Canada
  • Christchurch, New Zealand
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2006
First posted
Jul 7, 2006
Start
Aug 2006
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Feb 26, 2010
Last update
Sep 18, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00349336
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 7, 2006
Start date
Aug 2006
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Feb 26, 2010
Last update
Sep 18, 2012

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xelox

Start the discussion